TY  - CHAP
M1  - Book, Section
TI  - Genetic and Molecular Changes in Lung Cancer: Prospects for a Personalized Pharmacological Approach to Treatment
A1  - Li, Howard
A1  - Kern, Jeffrey A.
A2  - Grippi, Michael A.
A2  - Elias, Jack A.
A2  - Fishman, Jay A.
A2  - Kotloff, Robert M.
A2  - Pack, Allan I.
A2  - Senior, Robert M.
A2  - Siegel, Mark D.
PY  - 2015
T2  - Fishman's Pulmonary Diseases and Disorders, 5e
AB  - Lung  cancer  is  the  most  common  cause  of  cancer-related  death  in  men  and  women  worldwide,  responsible  for  over  1  million  deaths  annually.1  Each  year,  more  people  die  of  lung  cancer  than  of  the  next  three  leading  causes  of  cancer  death  combined:  breast,  colon,  and  prostate  cancer.  Despite  advances  in  surgical  techniques  and  combined  therapies,  lung  cancer  remains  a  disease  with  a  dismal  prognosis.  Although  1-year  survival  has  improved  over  the  past  few  decades,  overall  5-year  survival  has  remained  relatively  unchanged  at  12%  to  16%  over  the  past  30  years.2  These  data  underscore  the  need  to  develop  new  diagnostic  modalities  and  therapeutic  approaches  to  target  lung  cancer.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/18
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1122366977
ER  -